Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Blood. 2021 Nov 18;138(20):2002-2005. doi: 10.1182/blood.2021012039.

Marit Jalink^{1

2}, Sigbjørn Berentsen³, Jorge J Castillo⁴, Steven P Treon⁴, Marjan Cruijsen⁵, Bruno Fattizzo^{6

7}, Ramona Cassin⁶, Despina Fotiou⁸, Efstathios Kastritis⁸, Masja De Haas^{9

10}, Liesbeth E M Oosten⁹, Henrik Frederiksen¹¹, Andrea Patriarca¹², Shirley D'Sa¹³, Josephine M I Vos^{2

10

14}

¹ Center for Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands.
² Department of Hematology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands.
³ Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway.
⁴ Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
⁵ Department of Hematology, Catharina Hospital, Eindhoven, The Netherlands.
⁶ Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milano, Italy.
⁷ Department of Oncology and Oncohematology, University of Milan, Milan, Italy.
⁸ Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
⁹ Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
¹⁰ Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands.
¹¹ Department of Hematology, Odense University Hospital, Odense, Denmark.
¹² Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
¹³ UCLH Centre for Waldenström's Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom; and.
¹⁴ Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.

No abstract available

Publication types